NAS:BGNE (Cayman Islands) Also Trade In: Germany Hongkong Mexico

BeiGene Ltd $ 280.65 -1.75 (-0.62%)

Volume:
227,587
Avg Vol (1m):
243,814
Market Cap $:
25.12 Bil
Enterprise Value $:
22.34 Bil
P/E (TTM):
0.00
P/B:
8.51
Warning! GuruFocus has detected 5 Severe warning signs with BGNE. Click here to check it out.
5D 3M YTD 1Y 5Y 10Y All 10Y (-%)

BeiGene Ltd News and Headlines -

GuruFocus Articles Total 10
  • 1

Hillhouse's research methodology

"Time is a friend of great businesses and great entrepreneurs."

- Zhang Lei

On Zhang Lei's bookshelf, there was another book that stood out to me – "Security Analysis" (1934 edition) by Benjamin Graham and David Dodd.

This is likely surprising to many people because few, if any, associate Zhang with Ben Graham. In fact, Hillhouse's investments often befuddle value investors because Hillhouse is more than willing to bet big on companies with no current net earnings (such as JD.com (JD)) and sometimes even without current revenue (as is the case with BeiGene (BGNE)). Therefore,

94 Views    Grahamites    2020-09-28 16:04
Largest insider trades of the week

The GuruFocus All-in-One Screener can be used to find insider trades from a specific period of time or for a certain range of values. For these stock picks, I went under the Insiders tab and changed the settings for All Insider Buying to “$2,000,000+,” the duration to “July 2020” and All Insider Sales to “$2,000,000+.”

According to these filters, the following are this past week's most significant trades from company insiders.

Texas Pacific Land Trust

Horizon Kinetics Asset Management, 10% owner of Texas Pacific Land Trust (TPL), bought a combined 580 shares for an average price of $107

99 Views    Tiziano Frateschi    2020-07-10 14:11
Shares of South Korean company scheduled to start trading in January followed by launch of its first US drug

A South Korean pharmaceutical company plans to go public next month in an offering aimed at raising $850 million. The initial public offering comes on the heels of the Food and Drug Administration's approval of the company’s epilepsy drug. Last week, GuruFocus reported that another Asian company, Beijing-based BeiGene (BGNE), became the first Chinese company to get FDA approval of a drug discovered in that country. Now SK Biopharmaceuticals is poised to become the first South Korean company to independently discover, develop and launch a drug in the U. S.

FiercePharma reported that SK

89 Views    Barry Cohen    2019-12-02 23:02
Beijing-based company is first to gain FDA approval for a drug discovered by a Chinese company

It’s a good bet that not many who follow the pharmaceutical industry were familiar with the Chinese company BeiGene (BGNE). They should be now. Biotech giant AMGEN (AMGN) recently spent $2.7 billion for 20% ownership of the Beijing-based company.

The agreement calls for BeiGene to help Amgen commercialize its cancer treatments in China. In addition, it will take part in research and development work on 20 Amgen oncology drugs. Amgen said the deal would enable it to significantly speed up its oncology presence in China and would involve both companies advancing its pipeline there, according to an article

160 Views    Barry Cohen    2019-11-26 22:54
Several pharmaceutical companies make the list

According to the GuruFocus All-in-One Guru Screener, the following stocks have outperformed the Standard & Poor's 500 index over the past 12 months and were bought by gurus during the third quarter.

BeiGene Ltd. (BGNE) has a market cap of $8.29 billion. It has outperformed the S&P 500 Index by 39.9% over the past 12 months.

335852425.png

The stock is trading with a price-book ratio of 4.17. The share price is 50.86% above its 52-week low and 34.65% below its 52-week high.

The biopharmaceutical company has a profitability and growth rating of 3 out of

86 Views    Tiziano Frateschi    2019-01-17 20:07
JPMorgan initiates coverage of BeiGene, Brookline Capital Markets starts covering Celsion and Cellectar Biosciences

Analysts took action on health care stocks on Tuesday.

JPMorgan commenced coverage of BeiGene Ltd. (BGNE) with an overweight rating. The analyst established a price target of $174 per share, which represents 38.3% upside from the share price of $125.8 at market close on Tuesday.

The share price has increased 46% over the 52 weeks of trading through Nov. 20. It is trading below the 50-, 100- and 200-day simple moving average lines.

The 52-week range is $77.54 to $220.1 per share. The stock has a market capitalization of $7.15 billion, a price-book ratio of 3.77

77 Views    Alberto Abaterusso    2018-11-21 19:53
Fund releases 3rd-quarter portfolio

In its third-quarter portfolio, the Matthews Asia Small Companies Fund (Trades, Portfolio) disclosed it established 11 new positions.

Managed by Lydia So, Beini Zhou and Tiffany Hsiao, the fund seeks to achieve long-term capital appreciation by investing in small Asian companies, excluding Japanese companies, that are capable of sustaining growth based on a number of factors.

The fund’s five largest new buys for the quarter were Chief Telecom Inc. (ROCO:6561), Bilibili Inc. (BILI), FPT Digital Retail JSC (STC:FRT), China YuHua Education Corp. Ltd. (HKSE:06169) and BeiGene Ltd. (HKSE:06160).

Chief Telecom

The fund invested in 958,000 shares of

323 Views    Sydnee Gatewood    2018-11-06 19:38
The fund favored two industries within the sector

The Vanguard Health Care Fund (Trades, Portfolio), managed my Jean Hynes, bought six new positions in the third quarter, it revealed Monday.

The new positions represented two industries equally: biotech, and medical diagnostics and research. The three from biotech were: bluebeard bio Inc. (BLUE), BeiGene Ltd. (BGNE) and Galapagos NV (XAMS:GLPG). Medical instruments and diagnostics companies were: Essilor International SA (XPAR:EI), DexCom Inc. (DXCM) and PRA Health Sciences Inc. (PRAH).

The portfolio of the Vanguard Health Care Fund (Trades, Portfolio) had 80 positions as of the end of the third quarter. Together, they had

965 Views    Holly LaFon    2017-10-30 21:45
Company gives update on new treatments

AbbVie Inc. (ABBV) closed the third quarter reporting adjusted diluted EPS of $1.21, 4% lower than its second quarter of 2016 EPS of $1.26, and 7.07% higher than the third quarter of 2015.

The biopharmaceutical company, which was founded in 2013 as a spinoff of Abbott Laboratories (ABT) and headquartered in Lake Bluff, Illinois, beat analysts’ expectations on third quarter adjusted EPS by one cent and generated a positive surprise of 0.80%.

Source: Yahoo Finance

Concerning revenue for the third quarter of 2016, AbbVie reported revenue of $6.4 billion, a 7.7% increase on a year

901 Views    Alberto Abaterusso    2016-11-01 16:53
Preliminary data shows treatment is well tolerated and highly active

At the ninth International Workshop on Waldenstr

2380 Views    Alberto Abaterusso    2016-10-07 20:30

Headlines Total 170
  • 1
  • 2

2020-09-27
6:12am
2020-09-16 $ 255.13 (-0.12%)
5:15pm
2020-09-02 $ 234.94 (-0.58%)
5:15pm
2020-08-30
4:22am
2020-08-21 $ 240.52 (2.21%)
5:15pm
9:47am
2020-08-18 $ 231.96 (3.79%)
3:38pm
2020-08-14 $ 210.72 (-2.16%)
5:15pm
2020-08-07 $ 220.5 (-1.59%)
11:00am
7:00pm
2020-08-06 $ 224.06 (-1.3%)
7:15am
2020-08-05 $ 227.01 (1.96%)
7:00am
2020-07-27 $ 224 (-0.2%)
11:00am
2020-07-22 $ 235.9 (-4.95%)
6:15pm
2020-07-17 $ 248.67 (7.38%)
11:00am
2020-07-16 $ 231.59 (-3.23%)
9:31am
7:00pm
2020-07-14 $ 236.95 (11.24%)
3:43pm
7:43am
2020-07-13 $ 213.01 (8.66%)
9:11am
11:00pm
2020-07-08 $ 204.1 (3.82%)
5:15pm
2020-07-02 $ 195.86 (3.53%)
7:00am
2020-07-01 $ 189.18 (0.41%)
7:00am
7:01pm
2020-06-25 $ 186.15 (-0.69%)
9:15pm
2020-06-19 $ 182.67 (2.97%)
3:00am
2020-06-18 $ 177.4 (1.7%)
7:00am
2020-06-12 $ 163.92 (0.43%)
3:00am
2020-06-05 $ 172.03 (0.3%)
7:00am
2020-06-03 $ 169.04 (0.42%)
7:00am
2020-05-29 $ 165.54 (1.96%)
11:04am
11:02am
2020-05-27 $ 163.9 (3%)
7:02pm
2020-05-21 $ 164.6 (-0.72%)
7:02am
2020-05-20 $ 165.8 (-1.79%)
7:00am
2020-05-15 $ 166.26 (1.85%)
7:00am
2020-05-14 $ 163.24 (1.85%)
11:05am
2020-05-12 $ 163.26 (4.11%)
7:02pm
2020-05-05 $ 143.5 (4.36%)
4:15pm
2020-04-30 $ 161.62 (-0.92%)
7:00pm
2020-04-21 $ 161.03 (2.29%)
7:00pm
2020-04-14 $ 148.51 (-1.26%)
7:00pm
2020-04-11 $ 150.4 (%)
7:00pm
2020-03-25 $ 121.84 (-5.75%)
11:00am
2020-03-09 $ 153.07 (-0.16%)
3:00pm
2020-03-03 $ 164.06 (3.61%)
7:01pm
2020-02-25 $ 158.58 (-3.28%)
7:00am
2020-01-21 $ 169.67 (-0.41%)
7:00am
2020-01-13 $ 163.8 (0.49%)
7:01am
2020-01-08 $ 161.33 (-1.17%)
7:00am
2020-01-02 $ 165.92 (0.1%)
11:00am
2019-12-28
11:00am
11:00pm
2019-12-23
7:00pm
2019-12-19 $ 168.47 (0.93%)
4:15pm
2019-12-16 $ 165.09 (-6.21%)
7:00am
2019-12-13 $ 176.03 (-1.75%)
7:00am
2019-12-09
7:00pm
2019-11-29 $ 203.29 (-0.47%)
3:00pm
2019-11-26 $ 203.33 (-1.05%)
4:54pm
7:00am
2019-11-23
7:00am
2019-11-21 $ 203.31 (-0.29%)
7:15pm
2019-11-15 $ 196.4 (-0.46%)
7:00pm
2019-11-13 $ 197.3 (0.5%)
3:00pm
7:02pm
2019-11-11
7:00pm
2019-11-08 $ 192.89 (1.74%)
7:02pm
2019-11-06 $ 189.59 (-0.25%)
11:00am
2019-11-01 $ 138.34 (-0.52%)
7:00pm
2019-10-30 $ 138.86 (-1.43%)
11:00pm
2019-10-19 $ 132.28 (-0.74%)
7:00pm
2019-10-08 $ 120.51 (-1.42%)
11:00pm
2019-10-07 $ 120.51 (-1.42%)
3:00pm
2019-10-01 $ 122.46 (0.72%)
11:00pm
2019-09-30 $ 122.46 (0.72%)
11:00am
7:00am
2019-09-27 $ 128.12 (-1.44%)
7:00pm
2019-09-25 $ 129.99 (-2.5%)
11:00am
2019-09-24 $ 135.07 (-0.33%)
11:00pm
2019-09-23
7:00pm
2019-09-20 $ 132.95 (1.57%)
7:00pm
2019-09-18 $ 130.9 (-1.67%)
11:00am
11:00pm
2019-09-14 $ 134.19 (0.83%)
7:00pm
2019-09-12 $ 128.08 (0.49%)
7:00pm
2019-09-11 $ 128.08 (0.49%)
3:00pm
2019-09-08
3:00am
2019-09-03 $ 145.54 (1.25%)
11:01am
2019-08-22 $ 146.04 (0.61%)
7:00pm
2019-08-09 $ 133.48 (2.03%)
7:00pm
2019-07-08
11:00pm
2019-06-28 $ 123.95 (-1.36%)
11:02am
2019-06-20 $ 121.18 (1.06%)
11:02am
7:00am
2019-06-19 $ 119.91 (2.9%)
11:01am
2019-06-18 $ 116.53 (2.23%)
7:00am
2019-06-17 $ 113.99 (-3.09%)
7:00am
2019-06-14 $ 117.62 (-5.97%)
3:00am
Total 170
  • 1
  • 2